
ProPhase Labs (PRPH) Stock Forecast & Price Target
ProPhase Labs (PRPH) Analyst Ratings
Bulls say
ProPhase Labs Inc. is poised for significant financial growth, evidenced by its plan to increase lozenge production capacity by over 400% by December 2024, responding to robust market demand. The anticipated commercial launch of Equivir, coupled with positive preliminary clinical results, could significantly enhance the company’s top-line revenue, with forecasts suggesting Pharmaloz could generate $15 million in annualized revenue as early as 1Q24 and reach $30-$35 million by early 3Q24. Additionally, recent investments in automation are expected to boost production capacity substantially, which aligns with the company's 100% year-over-year growth in its non-Cold-EEZE contract manufacturing division.
Bears say
ProPhase Labs Inc. reported a total revenue of $8.4 million for the latest quarter, indicating a significant 65% year-over-year decline and falling short of the projected $12.3 million. The sharp decline in revenue was primarily attributed to an $18 million decrease in the diagnostic services segment, despite a slight offset from a $2.2 million increase in consumer products. The company faces several operational risks, including challenges in expanding manufacturing capacity, achieving market adoption for personal genomics products, and maintaining steady revenue streams from dietary supplements, which contribute to a negative outlook on its stock performance.
This aggregate rating is based on analysts' research of ProPhase Labs and is not a guaranteed prediction by Public.com or investment advice.
ProPhase Labs (PRPH) Analyst Forecast & Price Prediction
Start investing in ProPhase Labs (PRPH)
Order type
Buy in
Order amount
Est. shares
0 shares